EMA Authorised: Parsabiv (etelcalcetide hydrochloride) — Amgen Europe B.V.

View source ↗

Summary

Parsabiv (etelcalcetide hydrochloride) has been authorized by EMA for secondary hyperparathyroidism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• Parsabiv (etelcalcetide)

Snippet

Status: Authorised. Therapeutic area: Hyperparathyroidism, Secondary. MAH: Amgen Europe B.V.. Decision date: 12/08/2026